TY - JOUR
T1 - Arsenic trioxide and the phosphoinositide 3-kinase/Akt pathway in chronic lymphocytic leukemia
AU - Goussetis, Dennis J.
AU - Platanias, Leonidas C.
PY - 2010/9/1
Y1 - 2010/9/1
N2 - Simultaneous targeting of the phosphoinositide 3-kinase (PI3K)/Akt pathway increases arsenic trioxide (ATO) - dependent cytotoxicity of chronic lymphocytic leukemia (CLL) cells, whereas it has no significant effects on normal lymphocytes. Combinations of ATO with small molecules that target PI3K and/or Akt may provide a novel approach for the treatment of CLL. Clin Cancer Res; 16(17); 4311-2.
AB - Simultaneous targeting of the phosphoinositide 3-kinase (PI3K)/Akt pathway increases arsenic trioxide (ATO) - dependent cytotoxicity of chronic lymphocytic leukemia (CLL) cells, whereas it has no significant effects on normal lymphocytes. Combinations of ATO with small molecules that target PI3K and/or Akt may provide a novel approach for the treatment of CLL. Clin Cancer Res; 16(17); 4311-2.
UR - http://www.scopus.com/inward/record.url?scp=77956256946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956256946&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-10-1496
DO - 10.1158/1078-0432.CCR-10-1496
M3 - Comment/debate
C2 - 20622048
AN - SCOPUS:77956256946
SN - 1078-0432
VL - 16
SP - 4311
EP - 4312
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 17
ER -
